Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Table 4 Composite outcome representing treatment success after 18 months for each treatment group

Second-line treatment	N	HbA1c reduction ≥ 0.5% (≥ 5.5 mmol/mol)	Weight-loss ≥ 2 kg	No treatment change over 18 months	Overall success (i.e. attained all three endpoints)
MET + SU	847	559 (66.0)	217 (25.6)	478 (56.4)	81 (9.6)
MET + DPP-4i	608	335 (55.1)	260 (42.8)	300 (49.3)	104 (17.1)
MET + SGLT-2i	74	53 (71.6)	53 (71.6)	41 (55.4)	27 (36.5)
Other*	187	105 (56.2)	61 (32.6)	91 (48.7)	17 (9.1)
Overall	1716	1052 (61.3)	591 (34.4)	910 (53.0)	229 (13.3)

Data are in n (%). Data from all patients who had both HbA1c and weight measurements available at baseline and at 18 months
DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SU sulfonylurea
*Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies

ISSN: 1741-7015